<DOC>
	<DOCNO>NCT00651235</DOCNO>
	<brief_summary>To assess efficacy angiotensin II receptor blocker , Losartan , prevent progressive dilation aortic root patient Marfan syndrome .</brief_summary>
	<brief_title>A Randomized , Open-label , LOSARTAN Therapy Progression Aortic Root Dilation Patients With Marfan Syndrome</brief_title>
	<detailed_description>Marfan syndrome ( MFS ) multisystem connective tissue disorder autosomal dominant inheritance1 . The cardinal feature note cardiovascular , ocular , skeletal system . The life-threatening complication MFS progressive aortic root dilation lead aortic dissection rupture . Losartan , angiotensin II type I receptor ( AT1 ) antagonist , drug already clinical use hypertension type II diabetic nephropathy . A recent study show Losartan prevents aortic root dilation lung problem mouse model MFS . Therefore , goal clinical trial examine efficacy safety Losartan patient Marfan syndrome aortic root dilation prevention .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Marfan Syndrome</mesh_term>
	<mesh_term>Arachnodactyly</mesh_term>
	<mesh_term>Atenolol</mesh_term>
	<mesh_term>Propranolol</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>Inclusion criterion Marfan syndrome recognize aortic root dilation Patients must older one year age Betablocker treatment least three month Must sign inform consent form Exclusion criterion Prior aortic root surgery Aortic root dimension 5.5cm Aortic surgery within 6 month Diabetes mellitus liver renal dysfunction asthma Pregnancy Intolerance Losartan therapy</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
</DOC>